Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.9K
3.9K
MicroRNAs01:22

MicroRNAs

4.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

24.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.7K
Experimental RNAi02:15

Experimental RNAi

8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

14.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
14.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors limiting the extent of absolute bioavailability of pradefovir in rat.

Xenobiotica; the fate of foreign compounds in biological systems·2016
Same author

Three-dimensional piezoelectric vibration energy harvester using spiral-shaped beam with triple operating frequencies.

The Review of scientific instruments·2016
Same author

Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.

Oncotarget·2016
Same author

Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer.

Journal of experimental & clinical cancer research : CR·2016
Same author

Iodine Status of Vulnerable Populations in Henan Province of China 2013-2014 After the Implementation of the New Iodized Salt Standard.

Biological trace element research·2016
Same author

Establishment and comparison of three novel methods for the determination of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in human serum.

Journal of pharmaceutical and biomedical analysis·2016

Related Experiment Video

Updated: Apr 8, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer.

Yin-Jie Su1, Jin Yu2, Ya-Qin Huang3

  • 1Trainee Brigade, the Third Military Medical University, Chongqing 400038, China. yinjiesu@tmmu.edu.cn.

International Journal of Molecular Sciences
|June 26, 2015
PubMed
Summary

Long noncoding RNA (lncRNA) plays a critical role in prostate cancer development. Aberrant lncRNA expression impacts diagnosis and risk, offering new therapeutic strategies for this common malignancy.

Keywords:
biomarkerlong noncoding RNAprostate cancertherapeutic target

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.2K

Related Experiment Videos

Last Updated: Apr 8, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is the second most common visceral malignancy in men in Western countries.
  • The development of prostate cancer involves a complex malignant network.
  • Long noncoding RNAs (lncRNAs) have emerged as critical regulators in various cancers, including prostate cancer.

Purpose of the Study:

  • To review and synthesize current literature evidence on the role of lncRNAs in prostate cancer.
  • To highlight the association between aberrant lncRNA expression and prostate cancer diagnosis, risk stratification, and carcinogenesis.
  • To explore the potential of lncRNAs as novel biomarkers and therapeutic targets for prostate cancer.

Main Methods:

  • Comprehensive literature search and review of studies investigating lncRNAs in prostate cancer.
  • Analysis of data linking lncRNA expression patterns to clinical outcomes, including diagnosis and prognosis.
  • Synthesis of findings to elucidate the molecular mechanisms underlying lncRNA involvement in prostate carcinogenesis.

Main Results:

  • Aberrant expression of specific lncRNAs is frequently observed in prostate cancer patients.
  • LncRNAs are significantly associated with key aspects of prostate cancer, including diagnosis, risk stratification, and the carcinogenic process.
  • These findings provide novel insights into the intricate intracellular environment of prostate cancer.

Conclusions:

  • Long noncoding RNAs are integral to the molecular pathology of prostate cancer.
  • Understanding lncRNA dysregulation offers promising avenues for improving diagnostic accuracy and risk assessment.
  • Targeting lncRNAs may lead to the development of innovative prognostic and therapeutic strategies for prostate cancer patients.